PMID- 36388135 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20221119 IS - 2666-3546 (Electronic) IS - 2666-3546 (Linking) VI - 26 DP - 2022 Dec TI - Estimation of blood-based biomarkers of glial activation related to neuroinflammation. PG - 100549 LID - 10.1016/j.bbih.2022.100549 [doi] LID - 100549 AB - BACKGROUND: Neuroinflammation is a well-known feature of Alzheimer's disease (AD), and a blood-based test for estimating the levels of neuroinflammation would be expected. In this study, we examined and validated a model using blood-based biomarkers to predict the level of glial activation due to neuroinflammation, as estimated by (11)C-DPA-713 positron emission tomography (PET) imaging. METHODS: We included 15 patients with AD and 10 cognitively normal (CN) subjects. Stepwise backward deletion multiple regression analysis was used to determine the predictors of the TSPO-binding potential (BP(ND)) estimated by PET imaging. The independent variables were age, sex, diagnosis, apolipoprotein E4 positivity, body mass index and the serum concentration of blood-based biomarkers, including monocyte chemotactic protein 1 (MCP-1), fractalkine, chitinase 3-like protein-1 (CHI3L1), soluble triggering receptor expressed on myeloid cells 2 (sTREM2), and clusterin. RESULTS: Sex, diagnosis, and serum concentrations of MCP1 and sTREM2 were determined as predictors of TSPO-BP(ND) in the Braak1-3 area. The serum concentrations of MCP1 and sTREM2 correlated positively with TSPO-BP(ND). In a leave one out (LOO) cross-validation (CV) analysis, the model gave a LOO CV R(2) of 0.424, which indicated that this model can account for approximately 42.4% of the variance of brain TSPO-BP(ND.) CONCLUSIONS: We found that the model including serum MCP-1 and sTREM2 concentration and covariates of sex and diagnosis was the best for predicting brain TSPO-BP(ND). The detection of neuroinflammation in AD patients by blood-based biomarkers should be a sensitive and useful tool for making an early diagnosis and monitoring disease progression and treatment effectiveness. CI - (c) 2022 The Authors. FAU - Yasuno, Fumihiko AU - Yasuno F AD - National Hospital for Geriatric Medicine, National Center for Geriatrics and Gerontology, Obu, Japan. AD - Department of Clinical and Experimental Neuroimaging, Center for Development of Advanced Medicine for Dementia, National Center for Geriatrics and Gerontology, Obu, Japan. FAU - Watanabe, Atsushi AU - Watanabe A AD - Equipment Management Division, Center for Core Facility Administration, National Center for Geriatrics and Gerontology, Obu, Japan. FAU - Kimura, Yasuyuki AU - Kimura Y AD - National Hospital for Geriatric Medicine, National Center for Geriatrics and Gerontology, Obu, Japan. AD - Department of Clinical and Experimental Neuroimaging, Center for Development of Advanced Medicine for Dementia, National Center for Geriatrics and Gerontology, Obu, Japan. FAU - Yamauchi, Yumeka AU - Yamauchi Y AD - Equipment Management Division, Center for Core Facility Administration, National Center for Geriatrics and Gerontology, Obu, Japan. FAU - Ogata, Aya AU - Ogata A AD - Department of Clinical and Experimental Neuroimaging, Center for Development of Advanced Medicine for Dementia, National Center for Geriatrics and Gerontology, Obu, Japan. AD - Department of Pharmacy, Faculty of Pharmacy, Gifu University of Medical Science, Kani, Japan. FAU - Ikenuma, Hiroshi AU - Ikenuma H AD - Department of Clinical and Experimental Neuroimaging, Center for Development of Advanced Medicine for Dementia, National Center for Geriatrics and Gerontology, Obu, Japan. FAU - Abe, Junichiro AU - Abe J AD - Department of Clinical and Experimental Neuroimaging, Center for Development of Advanced Medicine for Dementia, National Center for Geriatrics and Gerontology, Obu, Japan. FAU - Minami, Hiroyuki AU - Minami H AD - National Hospital for Geriatric Medicine, National Center for Geriatrics and Gerontology, Obu, Japan. FAU - Nihashi, Takashi AU - Nihashi T AD - National Hospital for Geriatric Medicine, National Center for Geriatrics and Gerontology, Obu, Japan. FAU - Yokoi, Kastunori AU - Yokoi K AD - National Hospital for Geriatric Medicine, National Center for Geriatrics and Gerontology, Obu, Japan. FAU - Hattori, Saori AU - Hattori S AD - Department of Clinical and Experimental Neuroimaging, Center for Development of Advanced Medicine for Dementia, National Center for Geriatrics and Gerontology, Obu, Japan. FAU - Shimoda, Nobuyoshi AU - Shimoda N AD - Molecular Analysis Division, Center for Core Facility Administration, National Center for Geriatrics and Gerontology, Obu, Japan. FAU - Kasuga, Kensaku AU - Kasuga K AD - Department of Molecular Genetics, Brain Research Institute, Niigata University, Niigata, Japan. FAU - Ikeuchi, Takeshi AU - Ikeuchi T AD - Department of Molecular Genetics, Brain Research Institute, Niigata University, Niigata, Japan. FAU - Takeda, Akinori AU - Takeda A AD - National Hospital for Geriatric Medicine, National Center for Geriatrics and Gerontology, Obu, Japan. FAU - Sakurai, Takashi AU - Sakurai T AD - National Hospital for Geriatric Medicine, National Center for Geriatrics and Gerontology, Obu, Japan. FAU - Ito, Kengo AU - Ito K AD - National Hospital for Geriatric Medicine, National Center for Geriatrics and Gerontology, Obu, Japan. AD - Department of Clinical and Experimental Neuroimaging, Center for Development of Advanced Medicine for Dementia, National Center for Geriatrics and Gerontology, Obu, Japan. FAU - Kato, Takashi AU - Kato T AD - National Hospital for Geriatric Medicine, National Center for Geriatrics and Gerontology, Obu, Japan. AD - Department of Clinical and Experimental Neuroimaging, Center for Development of Advanced Medicine for Dementia, National Center for Geriatrics and Gerontology, Obu, Japan. LA - eng PT - Journal Article DEP - 20221105 PL - United States TA - Brain Behav Immun Health JT - Brain, behavior, & immunity - health JID - 101759062 PMC - PMC9650015 OTO - NOTNLM OT - Alzheimer's disease (AD) OT - Blood-based biomarkers OT - Monocyte chemotactic protein 1 (MCP-1) OT - Neuroinflammation OT - Positron emission tomography (PET) OT - Soluble triggering receptor expressed on myeloid cells 2 (sTREM2) COIS- The authors declare no potential conflicts of interest. EDAT- 2022/11/18 06:00 MHDA- 2022/11/18 06:01 PMCR- 2022/11/05 CRDT- 2022/11/17 12:07 PHST- 2022/07/19 00:00 [received] PHST- 2022/10/08 00:00 [revised] PHST- 2022/10/30 00:00 [accepted] PHST- 2022/11/17 12:07 [entrez] PHST- 2022/11/18 06:00 [pubmed] PHST- 2022/11/18 06:01 [medline] PHST- 2022/11/05 00:00 [pmc-release] AID - S2666-3546(22)00139-9 [pii] AID - 100549 [pii] AID - 10.1016/j.bbih.2022.100549 [doi] PST - epublish SO - Brain Behav Immun Health. 2022 Nov 5;26:100549. doi: 10.1016/j.bbih.2022.100549. eCollection 2022 Dec.